FDA Announces Removal of 12 Peptides from Category 2 and Schedules PCAC Meetings to Consider Adding Peptides to 503A Bulk Drug Substances List Obesity Management Clinical Drug Topics FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn FDA takes first step in possible reversal of ban on some peptides The Washington Post FDA Peptide Reclassification 2026: What It Means for Providers